Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units

BMC Clinical Pharmacology

Hugo Lövheim¹  Stig Karlsson³  Maria Gustafsson² 

[1]Hugo Lövheim, Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden

[2]Maria Gustafsson, Department of Pharmacology and Clinical Neuroscience, Umeå University, 901 85, Umeå, Sweden

[3]Stig Karlsson, Department of Nursing, Umeå University, Umeå, Sweden

关键词: Passiveness;    Aggression;    Inappropriate prescribing;    BPSD;    Dementia;    Antipsychotic prescribing;   

Others  :  860645
DOI  :  10.1186/2050-6511-14-10

 received in 2012-09-17, accepted in 2013-02-04,  发布年份 2013

【 摘 要 】

Background

Antipsychotic drugs are widely used for the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD), despite their limited efficacy and concerns about safety. The aim of this study was to describe antipsychotic drug therapy among people with dementia living in specialized care units in northern Sweden.

Methods

This study was conducted in 40 specialized care units in northern Sweden, with a total study population of 344 people with dementia. The study population was described in regard to antipsychotic drug use, ADL function, cognitive function and BPSD, using the Multi-Dimensional Dementia Assessment Scale (MDDAS). These data were collected at baseline and six months later. Detailed data about antipsychotic prescribing were collected from prescription records.

Results

This study showed that 132 persons (38%) in the study population used antipsychotic drugs at the start of the study. Of these, 52/132 (39%) had prescriptions that followed national guidelines with regard to dose and substance.

After six months, there were 111 of 132 persons left because of deaths and dropouts. Of these 111 people, 80 (72%) were still being treated with antipsychotics, 63/111 (57%) with the same dose. People who exhibited aggressive behavior (OR: 1.980, CI: 1.515-2.588), or passiveness (OR: 1.548, CI: 1.150-2.083), or had mild cognitive impairment (OR: 2.284 CI: 1.046-4.988), were at increased risk of being prescribed antipsychotics.

Conclusion

The prevalence of antipsychotic drug use among people with dementia living in specialized care units was high and inappropriate long-term use of antipsychotic drugs was common.

【 授权许可】

   
2013 Gustafsson et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Läkemedelsverket: Beteendemässiga och psykiska symtom vid demenssjukdom – BPSD [In English: Drug therapy and treatment for Behavioral and Psychological Symptoms of dementia – BPSD. Information from the Medical Products Agency]. Retrieved June 10, 2012 from http://www.lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/BPSD_bakgrund_webb.pdf webcite
• [2]Liperoti R, Pedone C, Corsonello A: Antipsychotics for the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD). Current Neuropharmacology 2008, 6:117-124.
• [3]Cerejeira J, Lagarto L, Mukaetova-Ladinska EB: Behavioral and psychological symptoms of dementia. Frontiers in Neurology 2012, 3:73.
• [4]Lövheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y: Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 2006, 18:713-26.
• [5]Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J Am Med Assoc 2005, 293:596-608.
• [6]Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Eng J Med 2006, 355:1525-1538.
• [7]Neil W, Curran S, Wattis J: Antipsychotic prescribing in older people. Age Ageing 2003, 32:475-483.
• [8]Gareri P, De Fazio P, Stilo MA, Ferreri G, De Sarro G: Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Investig 2003, 23:287-322.
• [9]Gareri P, Cortoneo A, Marchisio U, Curcio M, De Sarro G: Risperidone in the treatment of behavioral disorders in elderly patients with dementia. Arch Gerontol Geriatr Suppl 2001, 7:173-82.
• [10]Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G: Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006, 23:937-56.
• [11]Devanand DP, Sackeim HA, Brown RP, Mayeux R: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989, 46:854-857.
• [12]Melkersson KI, Dahl ML, Hulting AL: Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 2004, 175:1-6.
• [13]Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc 2005, 294:1934-1943.
• [14]Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA: Antipsychotic drug use and mortality in older adults in dementia. Ann Intern Med 2007, 146:775-786.
• [15]National Institute for Health and Clinical Excellence (NICE): Dementia - Supporting people with dementia and their careers in health and social care. Retrieved June 24, 2012 from: http://www.nice.org.uk/nicemedia/live/10998/30318/30318.pdf webcite
• [16]Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, Sykora K, Lipscombe L, Bell CM, Gurwitz JH: Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008, 168:1090-1096.
• [17]O’Connor DW, Griffith J, McSweeney K: Changes to psychotropic medications in the six month after admission to nursing homes in Melbourne, Australia. Int Psychogeriatr 2010, 22:1149-53.
• [18]Selbæk G, Kirkevold Ø, Engedal K: The course of psychiatric and behavioural symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes a 12-month follow-up study. Am J Geriatr Psychiatry 2008, 16:528-536.
• [19]Pellfolk TJ, Gustafson Y, Bucht G, Karlsson S: Effects of a restraint minimization program on staff knowledge, attitudes, and practice: a cluster randomized trial. J Am Geriatr Soc 2010, 58:62-9.
• [20]Sandman PO, Adolfsson R, Norberg A, Nyström L, Winblad B: Long-term care of the elderly. A descriptive study of 3600 institutionalized patients in the county of Vasterbotten, Sweden. Compr Gerontol A 1988, 2:120-132.
• [21]Adolfsson R, Gottfries CG, Nyström L, Winblad B: Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand 1981, 63:225-244.
• [22]Folstein MF, Folstein SE, McHugh PR: ”Mini-mental state”: a practical method for grading the cognitive state of patients for the clinican. J Psychiatr Res 1975, 12:189-198.
• [23]Lövheim H, Sandman PO, Karlsson S, Gustafson Y: Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. Int Psychogeriatr 2008, 20:777-89.
• [24]Eriksson L, Pelling H: Psykoser [In English: Psychoses]. In Läkemedelsboken. 2005/2006. Stockholm: Apoteket AB; 2005:806-814.
• [25]Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R: Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 1999, 159:1733-1740.
• [26]Ruths S, Straand J, Nygaard HA, Aarsland D: Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study – The Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry 2008, 23:889-895.
• [27]Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003, 64:134-143.
• [28]Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A, The HGEU Study Group: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000, 57:968-76.
• [29]Gareri P, Cotroneo A, Lacava R, Seminara G, Marigliano N, Loiacono A, De Sarro G: Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl 2004, 9:207-15.
• [30]Lövheim H, Gustafson Y, Karlsson S, Sandman PO: Comparison of behavioral and psychological symptoms of dementia and psychotropic drug treatments among old people in geriatric care in 2000 and 2007. Int Psychogeriatr 2011, 23:1616-22.
• [31]Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, Howard R: Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. Br Med J 2006, 332:756-61.
• [32]O’Connor DW, Ames D, Gardner B, King M: Psychosocial treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards. Int Psychogeriatr 2009, 21:241-251.
• [33]Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL: Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008, 42:32-38.
• [34]Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C: Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr 2010, 22:346-72.
• [35]Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin Ther 2004, 26:980-990.
• [36]Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastango KB, Chew ML: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002, 159:460-465.
• [37]Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic Multicentre study. Br J Psychiatry 1990, 157:894-901.
• [38]Lanctôt KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA: Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer‘s disease. Int J Geriatr Psychiatry 2002, 17:531-541.
• [39]Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Huber KA: A double-blind comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia. Am J Geriatr Psychiatry 2007, 15:942-52.
• [40]Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L: Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005, 17:617-29.